Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC Published 2024-06-02 Download video MP4 360p Recommendations 24:50 Lung Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Joshua Sabari 05:08 Consolidation Durvalumab Could Be New SOC in Limited-Stage SCLC 08:30 ASCO 2024 - LBA4: The LAURA Study 05:03 Tumour immunology and immunotherapy 03:17 Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC 19:08 Hormone Therapy & Side Effects For High-Risk (Gleason 8) #ProstateCancer | Mark Scholz, MD #PCRI 06:43 Neoadjuvant Nivolumab + Ipilimumab Could Be New SOC in Stage III Melanoma 04:35 Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung Cancer 04:46 First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma 06:20 ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial 05:03 Which is Better - Surgery vs. Radiation for Prostate Cancer? 28:22 How I Found Out I had Pancreatic Cancer - Matthew | The Patient Story 07:52 Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node–Only mUC 05:53 Targeted Therapy in Non-Small Cell Lung Cancer 38:36 Atrial Fibrillation: New Solutions for an Old Problem 02:17 TAGRISSO® (osimertinib): A Musician's Story 22:00 How I Live with Stage 4 Metastatic Prostate Cancer | Mark's Story | The Patient Story 32:12 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line Therapy 13:10 CAR T Cells: Beating Cancer with the Immune System 04:17 How does lung cancer affect the body? Similar videos 01:50 Consolidation therapy for unresectable stage III EGFR-mutant NSCLC 06:50 Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh Ramalingam 58:24 Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC 05:59 Targeted therapy in consolidation setting for lung cancer 09:49 Osimertinib as Frontline Therapy for EGFR-Positive NSCLC 1:11:21 Maximizing the Potential of Immunotherapy in Unresectable Stage III NSCLC 12:11 Clinical Clips in NSCLC Harboring EGFR Mutations: Cutting-Edge Reports from ASCO 2024 20:34 2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2 26:37 Col Dr G S Chaudhary | Real World Evidence Osimertinib as SoC in the management of EGFRm NSCLC 1:56:22 Optimizing treatment in Lung Cancer 01:02 Osimertinib for Treatment of EGFR+ Lung Cancer 1:59:49 Available Clinical Research in the Care of Patients with NSCLC with an EGFR Mutation 37:44 Deciphering the data in EGFR - Mutant NSCLC 06:20 Immunotherapy in Stage III NSCLC: Practice-Changing Results of PACIFIC Trial (BMIC-006) 04:56 ACTIVE trial update: EGFRm NSCLC 04:03 Treating Locally Advanced NSCLC: Additional Concerns 03:12 Concurrent Chemoradiotherapy in Stage III NSCLC 1:04:55 Treatment of Unresectable Stage 3 Non-Small Cell Lung Cancer More results